Table II.
Patient clinical characteristics.
| Characteristic | (n = 16) |
|---|---|
| Age, years | |
| Median | 68 |
| Range | 60–79 |
| Sex | |
| Female, % | 44 |
| Hemoglobin, g/dL | |
| Median | 9.1 |
| Range | 7.4–13.0 |
| Platelets, ×109/L | |
| Median | 50 |
| Range | 8–250 |
| WBC count, ×109/L | |
| Median | 3.7 |
| Range | 1.1–20.3 |
| PB blasts, % | |
| Median | 32 |
| Range | 0–85 |
| BM blasts, % | |
| Median | 63 |
| Range | 6–95 |
| Cytogenetics, n | |
| CBF | 0 |
| Normal | 2 |
| Complex (≥5 abnormalities) | 5 |
| Other | 9 |
| Disease status, n | |
| Refractory | 6 |
| Relapsed | 10 |
| CR duration (relapse patients), n | |
| 0–6 months | 6 |
| >6 months | 4 |
| No. of prior therapies | |
| Median | 1 |
| Range | 1–3 |
| Prior therapy, n | |
| HiDAC | 5 |
| Antisense | 3 |
WBC, white blood cell; PB, peripheral blood; BM, bone marrow; CBF, core binding factor; CR, complete remission; HiDAC, high-dose cytarabine.